药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Lumiracoxib
Pitolisant
The serum concentration of Vemurafenib can be decreased when it is combined with Pitolisant.
Lumiracoxib
Delamanid
Vemurafenib may increase the QTc-prolonging activities of Delamanid.
Lumiracoxib
Apalutamide
The serum concentration of Vemurafenib can be decreased when it is combined with Apalutamide.
Lumiracoxib
Ipilimumab
Ipilimumab may increase the hepatotoxic activities of Vemurafenib.
Lumiracoxib
Celiprolol
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Celiprolol.
Lumiracoxib
Dosulepin
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Dosulepin.
Lumiracoxib
Aripiprazole lauroxil
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aripiprazole lauroxil.
Lumiracoxib
Ebastine
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Ebastine.
Lumiracoxib
Lurasidone
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lurasidone.
Lumiracoxib
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Acetyldigoxin.
Lumiracoxib
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Vemurafenib.
Lumiracoxib
Rufloxacin
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Vemurafenib.
Lumiracoxib
Lidoflazine
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Vemurafenib.
Lumiracoxib
Piromidic acid
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Vemurafenib.
Lumiracoxib
Lorajmine
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Vemurafenib.
Lumiracoxib
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Vemurafenib.
Lumiracoxib
Prajmaline
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Vemurafenib.
Lumiracoxib
Bencyclane
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Vemurafenib.
Lumiracoxib
Cibenzoline
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Vemurafenib.
Lumiracoxib
Gallopamil
The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Vemurafenib.